Joint with: Fibrosis Frontiers: From Basic Mechanisms to Precision Therapies
Metabolic Approaches to Chronic Liver Disease

Mar 01–04, 2027 | Keystone Resort, Keystone, CO, United States
Scientific Organizers: Jay D. Horton, Bei B. Zhang, and Samuel Klein

  In Person
  On Demand
×

-

Mar 01–04, 2027 | Keystone Resort, Keystone, CO, United States

Scientific Organizers: Jay D. Horton, Bei B. Zhang, and Samuel Klein

Supported by the  Directors' Fund

***Meeting program subject to change.

Available Formats:   = In Person     = On Demand
Monday, March 1, 2027
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Tuesday, March 2, 2027
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
Helen H. Hobbs, University of Texas Southwestern Medical Center
Genetic Determinants of Chronic Liver Disease Progression
Role of Intrahepatic Lipid Metabolism in Steatotic Liver Diseases
9:00–11:15 AM
Jay D. Horton, University of Texas Southwestern Medical Center
Role of Intrahepatic Lipid Metabolism in Steatotic Liver Diseases
Peter A. Crawford, University of Minnesota
Ketogenesis and Fatty Acid Synthesis
Kathryn E. Wellen, University of Pennsylvania
New and Surprising Directions in de novo Lipogenesis
Brian N. Finck, Washington University
Interorgan Communication and Hepatic Lipogenesis
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Panel Discussion 1: What will be the Residual Risk if Patients are Placed in Incretin Therapy for Obesity? Then, What is the Residual Risk in MASH?
11:15–12:15 PM
Poster Setup
11:15–1:00 PM
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Molecular Drivers of Chronic Liver Disease
5:00–7:00 PM
Ana Maria Cuervo †, Albert Einstein College of Medicine
Role of Autophagy in Chronic Liver Disease
Peng Li †, Zengzhou University and Tsinghua University
Role of Lipid Droplet Proteins in MASLD
Orian S Shirihai, David Geffen School of Medicine at UCLA
Mitochondrial Function in Chronic Liver Disease
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Posters
7:30–10:00 PM
Wednesday, March 3, 2027
Breakfast
7:00–8:00 AM
Emerging Therapeutic Approaches to Treat Chronic Liver Diseases
8:00–11:00 AM
Bei B. Zhang, Novo Nordisk
Unraveling Complex Biology and Improving Cardiometabolic Health with New Therapies
Erik Ingelsson, Wave Life Sciences
Silencing INHBE to Achieve Healthy, Sustainable Weight Loss through Fat Burning, and Muscle Maintenance
Ruth E. Gimeno †, Eli Lilly and Company
Incretin therapies in MASLD
Gerald I Shulman, Yale University School of Medicine
Role of Uncouplers in Preventing MASLD Progression and Fibrosis
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Panel Discussion 2: Is Weight Loss Induced Loss in Muscle Mass a Problem?
11:00–12:00 PM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Peripheral Organ Contribution and Pathogenesis of Liver Fibrosis
5:00–7:00 PM
David A Brenner †, Sanford Burnham Prebys
Molecular Events Leading to Stellate Cell Activation and Fibrosis in Chronic Liver Disease
Timo D Müller, Helmholtz Munich
Improving Liver Health using Next Generation Incretin-Based Polyagonists
Liming Pei, Children's Hospital of Philadelphia/University of Pennsylvania
Pathogenesis and Mechanisms Underlying Fontan-Associated Liver Disease (FALD)
Sarah Ewald †, University of Virginia
Cachexia and Hepatic Fibrosis
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Posters
7:30–10:00 PM
Thursday, March 4, 2027
Breakfast
7:00–8:00 AM
Weight Loss and Exercise in MASLD Progression
8:00–11:00 AM
Samuel Klein, Washington University School of Medicine
Metabolic and Hepatic Implications of Weight Loss
Arun J. Sanyal †, Virginia Commonwealth University Medical Center
How Much Weight Loss is Needed to Effectively Impact MASLD and Fibrosis
Juleen R. Zierath, Karolinska Institutet
Exercise Medicine for MASLD
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Role of Peripheral Organs in Chronic Liver Disease Progression
5:00–6:45 PM
Caterina Conte, San Raffaele Roma University, Rome, Italy
Sarcopenia in Obesity and MASLD: Definition and Clinical Implications
Saswata Talukdar, Roche
Effect of Myostatin and Activin Inhibition on Muscle Mass, Strength and Function
Amalia Gastaldelli †, Institute of Clinical Physiology
Linking Glucose Metabolism to MASLD Progression
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Dinner
7:00–8:00 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Friday, March 5, 2027
Departure
12:00–11:59 PM

Subscribe for Updates